Chloride Channel Agonists
"Chloride Channel Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that stimulate chloride ion influx through cell membrane channels.
Descriptor ID |
D065101
|
MeSH Number(s) |
D27.505.519.562.311
|
Concept/Terms |
Chloride Channel Agonists- Chloride Channel Agonists
- Agonists, Chloride Channel
- Channel Agonists, Chloride
- Chloride Channel Activators
- Activators, Chloride Channel
- Channel Activators, Chloride
- Chloride Channel Stimulators
- Channel Stimulators, Chloride
- Stimulators, Chloride Channel
|
Below are MeSH descriptors whose meaning is more general than "Chloride Channel Agonists".
Below are MeSH descriptors whose meaning is more specific than "Chloride Channel Agonists".
This graph shows the total number of publications written about "Chloride Channel Agonists" by people in this website by year, and whether "Chloride Channel Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2016 | 0 | 1 | 1 |
2017 | 1 | 0 | 1 |
2018 | 3 | 1 | 4 |
2019 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Chloride Channel Agonists" by people in Profiles.
-
Negotiations between the NHS and Vertex on access to lumacaftor and ivacaftor become protracted. Lancet Respir Med. 2019 09; 7(9):739-740.
-
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials. J Cyst Fibros. 2019 09; 18(5):700-707.
-
A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosis-Associated Liver Disease. Liver Transpl. 2019 04; 25(4):640-657.
-
Emerging Concepts and Therapies for Mucoobstructive Lung Disease. Ann Am Thorac Soc. 2018 11; 15(Suppl 3):S216-S226.
-
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1599-1611.
-
Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. Am J Respir Crit Care Med. 2018 06 01; 197(11):1433-1442.
-
Ion Channel Modulators in Cystic Fibrosis. Chest. 2018 08; 154(2):383-393.
-
Restoration of CFTR Activity in Ducts Rescues Acinar Cell Function and Reduces Inflammation in Pancreatic and Salivary Glands of Mice. Gastroenterology. 2017 10; 153(4):1148-1159.
-
Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. Hum Mol Genet. 2016 10 15; 25(20):4590-4600.